Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Jackson, C.; Stevens, J.; Ren, S.; Latimer, N.; Bojke, L.; Manca, A.; Sharples, L. (2017)
Publisher: SAGE Publications
Languages: English
Types: Article
Subjects: Quality-Adjusted Life Years, Models, Statistical, Data Interpretation, Statistical, United Kingdom, internal medicine, Models, Economic, Uncertainty, multiparameter evidence synthesis, Survival Analysis, technology assessment, Cost-Benefit Analysis, Original Articles, Randomized Controlled Trials as Topic, Methods for Extrapolating Survival in Cost-Effectiveness Analyses, detailed methodology, Humans
This article describes methods used to estimate parameters governing long-term survival, or times to other events, for health economic models. Specifically, the focus is on methods that combine shorter-term individual-level survival data from randomized trials with longer-term external data, thus using the longer-term data to aid extrapolation of the short-term data. This requires assumptions about how trends in survival for each treatment arm will continue after the follow-up period of the trial. Furthermore, using external data requires assumptions about how survival differs between the populations represented by the trial and external data. Study reports from a national health technology assessment program in the United Kingdom were searched, and the findings were combined with “pearl-growing” searches of the academic literature. We categorized the methods that have been used according to the assumptions they made about how the hazards of death vary between the external and internal data and through time, and we discuss the appropriateness of the assumptions in different circumstances. Modeling choices, parameter estimation, and characterization of uncertainty are discussed, and some suggestions for future research priorities in this area are given.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. Available from: URL: https:// www.nice.org.uk/article/pmg9
    • 2. Latimer NR. Survival analysis for economic evaluations alongside clinical trials: extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743-54.
    • 3. Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32(5): 722-32.
    • 4. Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health Econ. 2009;19(1):43-55.
    • 5. Kleijnen S, George E, Goulden S, et al. Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions. Value Health. 2012;15(6):954-60.
    • 6. Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12(1):9.
    • 7. Imai K, King G, Stuart EA. Misunderstandings between experimentalists and observationalists about causal inference. J R Stat Soc Ser A Stat Soc. 2008;171(2):481-502.
    • 8. Hartman E, Grieve R. From sample average treatment effect to population average treatment effect on the treated: combining experimental with observational studies to estimate population treatment effects. J R Stat Soc Ser A Stat Soc. 2015; 178(3):757-78.
    • 9. Stuart EA, Cole SR, Bradshaw CP, Leaf PJ. The use of propensity scores to assess the generalizability of results from randomized trials. J R Stat Soc Ser A Stat Soc. 2001;174(2):369-86.
    • 10. Ramer SL. Site-ation pearl growing: methods and librarianship history and theory. J Med Libr Assoc. 2005;93(3):397-400.
    • 11. Imamura M, Abrams P, Bain C, et al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence. Health Technol Assess. 2010;14(40):1-188.
    • 12. Carlton J, Karnon J, Czoski-Murray C, Smith K, Marr J. The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation. Health Technol Assess. 2008;12(25):iii, xi-194.
    • 13. Speight P, Palmer S, Moles D, et al. The cost-effectiveness of screening for oral cancer in primary care. Health Technol Assess. 2006;10(14):1-144.
    • 14. Main C, Palmer S, Griffin S, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess. 2004; 8(40):1-141.
    • 15. Burch J, McKenna C, Palmer S, et al. Rimonabant for the treatment of overweight and obese people. Health Technol Assess. 2009;13(suppl 3):13-22
    • 16. Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, et al. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling. Health Technol Assess. 2005;9(27):1-158.
    • 17. Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with gastrointestinal stromal tumours. Health Technol Assess. 2005;9(25):1-142.
    • 18. Bond M, Pitt M, Akoh J, Moxham T, Hoyle M, Anderson R. The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model. Health Technol Assess. 2009;13(38):1-156.
    • 19. Takeda A, Cooper K, Bird A, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess. 2010;14(42):1-209.
    • 20. Grant A, Wileman S, Ramsay C. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastrooesophageal reflux disease: a UK collaborative study. The REFLUX Trial. Health Technol Assess. 2008;12(31):1-181.
    • 21. Peek GJ, Elbourne D, Mugford M, et al. Randomised controlled trial and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR). Health Technol Assess. 2010; 14(35):1-46.
    • 22. Chambers D, Paulden M, Paton F, et al. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess. 2010; 14(39):1-211.
    • 23. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007;11(26): 1-134.
    • 24. Main C, Pitt M, Moxham T, Stein K. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. Health Technol Assess. 2010;14(suppl 2):27-32.
    • 25. Aballe´a S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 2007;109(6):1082-90.
    • 26. Hisashige A, Yoshida S, Kodaira S. Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer. Br J Cancer. 2008;99(8):1232-8.
    • 27. Messori A, Trippoli S. A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review). Oncol Rep. 1999;6(5):1135-41.
    • 28. Viscomi S, Pastore G, Dama E, et al. Life expectancy as an indicator of outcome in follow-up of population-based cancer registries: the example of childhood leukemia. Ann Oncol. 2006; 17(1):167-71.
    • 29. Howard DH, Tangka FK, Seeff LC, Richardson LC, Ekwueme DU. The impact of detection and treatment on lifetime medical costs for patients with precancerous polyps and colorectal cancer. Health Econ. 2009;18(12):1381-93.
    • 30. Bagust A, Beale S. Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach. Med Decis Making. 2014;34(3):343-51.
    • 31. Boag J. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J R Stat Soc Ser B Stat Soc. 1949;11(1):15-53.
    • 32. Williams C, Brunskill S, Altman D, et al. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess. 2006; 10(34):1-204.
    • 33. Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. Health Technol Assess. 2009;13(31):1-77.
    • 34. Henriksson M, Epstein D, Palmer S, et al. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial. Heart. 2008;94: 717-23.
    • 35. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess. 2004;8(11):1-91.
    • 36. Rodgers M, Hodges R, Hawkins J, et al. Colour vision testing for diabetic retinopathy: a systematic review of diagnostic accuracy and economic evaluation. Health Technol Assess. 2009;13(60): 1-160.
    • 37. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006; 10(42):1-229.
    • 38. Chambers D, Epstein D, Walker S, et al. Endovascular stents for abdominal aortic aneurysms: a systematic review and economic model. Health Technol Assess. 2009;13(48):1-189.
    • 39. Fleurence R, Hollenbeak C. Rates and probabilities in economic modelling. Pharmacoeconomics. 2007;25(1):3-6.
    • 40. Demiris N, Sharples LD. Bayesian evidence synthesis to extrapolate survival estimates in cost-effectiveness studies. Stat Med. 2006;25(11):1960-75.
    • 41. Benaglia T, Jackson CH, Sharples LD. Survival extrapolation in the presence of cause specific hazards. Stat Med. 2014;34(5): 796-811.
    • 42. Rodgers M, McKenna C, Palmer S, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess. 2008;12(34):1-198.
    • 43. Stevenson M, Lloyd-Jones M, Papaioannou D. Vitamin K to prevent fractures in older women: systematic review and economic evaluation. Health Technol Assess. 2009;13(45):1-134.
    • 44. Black C, Sharma P, Scotland G, et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess. 2010;14(21):1-184.
    • 45. Louzada-Neto F. Polyhazard models for lifetime data. Biometrics. 1999;55(4):1281-5.
    • 46. Maetani S, Nakajima T, Nishikawa T. Parametric mean survival time analysis in gastric cancer patients. Med Decis Making. 2004;24(2):131-41.
    • 47. Fang CT, Chang YY, Hsu HM, et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM. 2007;100(2):97-105.
    • 48. Chu PC, Wang JD, Hwang JS, Chang YY. Estimation of life expectancy and the expected years of life lost in patients with major cancers: extrapolation of survival curves under highcensored rates. Value Heal. 2008;11(7):1102-9.
    • 49. Hwang J, Wang J. Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies. Stat Med. 1999; 18(13):1627-40.
    • 50. Breslow N, Day N. Statistical methods in cancer research. Volume II: the design and analysis of cohort studies. IARC Sci Publ. 1987;82:1-406.
    • 51. Andersson TM-LL, Dickman PW, Eloranta S, Lambe M, Lambert PC. Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Stat Med. 2013;32(30): 5286-300.
    • 52. Royston P, Parmar MKB. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30(19):2409-21.
    • 53. Davies A, Briggs A, Schneider J, et al. The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Res Med. 2012;3(1):e25-36.
    • 54. Jackson CH, Sharples LD, Thompson SG. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction. Int J Biostat. 2010;6(1):article 34.
    • 55. Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175-97.
    • 56. Guyot P, Welton NJ, Beasley M, Ades AE. Extrapolation of trial-based survival curves using external information. Value Health. 2014;17(7):A326.
    • 57. Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. The BUGS Book: A Practical Introduction to Bayesian Analysis. Boca Raton (FL): CRC Press; 2012.
    • 58. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265.
    • 59. Jackson CH. flexsurv: a platform for parametric survival modelling in R. J Stat Softw. In press.
    • 60. Nelson CL, Sun JL, Tsiatis AA, Mark DB. Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology. Stat Med. 2008; 27(26):5525-55.
    • 61. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570-9.
    • 62. Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD. A framework for addressing structural uncertainty in decision models. Med Decis Making. 2011;31(4):662-74.
    • 63. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester (UK): Wiley; 2004.
    • 64. Buxton M, Caine N, Chase D, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. Health Technol Assess. 2006;10(27):1-164.
    • 65. Welton NJ, Sutton AJ, Cooper N, Abrams KR, Ades AE. Evidence Synthesis for Decision Making in Healthcare. Chichester (UK): John Wiley & Sons; 2012.
    • 66. Jackson CH, Jit M, Sharples LD, De Angelis D. Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial. Med Decis Making. 2015;35(2):148-61.
    • 67. Bojke L, Claxton K, Bravo-Vergel Y, Sculpher M, Palmer S, Abrams K. Eliciting distributions to populate decision analytic models. Value Health. 2010;13(5):557-64.
    • 68. Soares MO, Bojke L, Dumville J, Iglesias C, Claxton K. Methods to elicit experts' beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration. Stat Med. 2011;30(19): 2363-80.
    • 69. O'Hagan A, Buck CE, Daneshkhah A, et al. Uncertain Judgements: Eliciting Experts' Probabilities. Chichester (UK): John Wiley & Sons; 2006.
    • 70. Greenland S. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. Int J Epidemiol. 2006;35(3):765-75.
    • 71. Strong M, Oakley JE, Chilcott J. Managing structural uncertainty in health economic decision models. J R Stat Soc Ser C (Applied Stat). 2012;61(1):25-45.
    • 72. Strong M, Oakley J. When is a model good enough? Deriving the expected value of model improvement via specifying internal model discrepancies. J Uncertain Quantif. 2014;2:106-25.
    • 73. Mahon R. Temporal uncertainty in cost-effectiveness decision models. PhD thesis. University of York; 2014.
  • No related research data.
  • No similar publications.

Share - Bookmark

Funded by projects

Cite this article